Market overview
The global inhalation drug delivery market is worth USD 40.1 bn in 2026 and is forecast to reach USD 68.5 bn by 2036, growing at a 5.5% CAGR. United States is the largest country market and Metered-dose inhalers is the largest by device type segment.
| Scope | Inhaled drug products and their delivery systems: metered-dose inhalers, dry-powder inhalers, soft-mist inhalers and nebulisers, valued at the sale of the drug-device product to patients and providers. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 38.0 bn |
| Value 2026 | USD 40.1 bn |
| Value 2036 | USD 68.5 bn |
| CAGR 2026-2036 | 5.5% |
| Volume 2026 | 1,462 million units |
| Volume 2036 | 2,261 million units |
| Average price 2026 | USD 27.4 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Inhalation Drug Delivery market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 40.1 bn |
| 2027 | USD 42.3 bn |
| 2028 | USD 44.6 bn |
| 2029 | USD 47.1 bn |
| 2030 | USD 49.7 bn |
| 2031 | USD 52.4 bn |
| 2032 | USD 55.3 bn |
| 2033 | USD 58.3 bn |
| 2034 | USD 61.5 bn |
| 2035 | USD 64.9 bn |
| 2036 | USD 68.5 bn |
Inhalation Drug Delivery market segmentation
By device type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Metered-dose inhalers | 42.0% | 38.0% | USD 16.8 bn | 4.5% |
| Dry-powder inhalers | 34.0% | 35.5% | USD 13.6 bn | 6.0% |
| Nebulisers | 16.0% | 15.9% | USD 6.4 bn | 5.5% |
| Soft-mist and other inhalers | 8.0% | 10.5% | USD 3.2 bn | 8.4% |
By indication
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Asthma | 38.0% | 33.9% | USD 15.2 bn | 4.3% |
| COPD | 40.0% | 39.3% | USD 16.0 bn | 5.3% |
| Cystic fibrosis and other respiratory | 8.0% | 8.6% | USD 3.2 bn | 6.3% |
| Systemic and other inhaled drugs | 14.0% | 18.2% | USD 5.6 bn | 8.3% |
By drug class
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Beta-agonists | 28.0% | 26.0% | USD 11.2 bn | 4.7% |
| Inhaled corticosteroids | 22.0% | 20.0% | USD 8.8 bn | 4.5% |
| Combination therapies | 32.0% | 34.0% | USD 12.8 bn | 6.1% |
| Antibiotics and other inhaled drugs | 18.0% | 20.0% | USD 7.2 bn | 6.6% |
By age group
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Adults under sixty-five | 52.0% | 50.0% | USD 20.8 bn | 5.1% |
| Seniors | 30.0% | 32.0% | USD 12.0 bn | 6.2% |
| Children | 18.0% | 18.0% | USD 7.2 bn | 5.5% |
By distribution
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retail pharmacy | 48.0% | 44.0% | USD 19.2 bn | 4.6% |
| Hospital pharmacy | 28.0% | 26.0% | USD 11.2 bn | 4.7% |
| Online and mail order | 24.0% | 30.0% | USD 9.6 bn | 7.9% |
Top 25 countries for inhalation drug delivery by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 82.5% of 2026 revenue and the 25 countries below together hold 95.1%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 18.0 bn | 45.0% | USD 31.2 bn | 5.6% |
| 2 | China | USD 3.2 bn | 8.0% | USD 5.5 bn | 5.6% |
| 3 | Japan | USD 2.4 bn | 6.0% | USD 3.6 bn | 4.2% |
| 4 | Germany | USD 2.0 bn | 5.0% | USD 3.2 bn | 4.6% |
| 5 | United Kingdom | USD 1.6 bn | 4.0% | USD 2.7 bn | 5.2% |
| 6 | France | USD 1.6 bn | 4.0% | USD 2.5 bn | 4.7% |
| 7 | Italy | USD 1.2 bn | 3.0% | USD 1.9 bn | 4.8% |
| 8 | Canada | USD 1.2 bn | 3.0% | USD 2.0 bn | 5.1% |
| 9 | Spain | USD 1.0 bn | 2.5% | USD 1.6 bn | 5.1% |
| 10 | Brazil | USD 802 mn | 2.0% | USD 1.6 bn | 7.0% |
| 11 | India | USD 682 mn | 1.7% | USD 1.6 bn | 9.2% |
| 12 | Australia | USD 545 mn | 1.4% | USD 877 mn | 4.9% |
| 13 | South Korea | USD 409 mn | 1.0% | USD 657 mn | 4.9% |
| 14 | Mexico | USD 409 mn | 1.0% | USD 822 mn | 7.2% |
| 15 | Russia | USD 341 mn | 0.8% | USD 548 mn | 4.9% |
| 16 | Turkey | USD 341 mn | 0.8% | USD 685 mn | 7.2% |
| 17 | Netherlands | USD 341 mn | 0.8% | USD 548 mn | 4.9% |
| 18 | Poland | USD 273 mn | 0.7% | USD 438 mn | 4.9% |
| 19 | Saudi Arabia | USD 273 mn | 0.7% | USD 548 mn | 7.2% |
| 20 | Switzerland | USD 273 mn | 0.7% | USD 438 mn | 4.9% |
| 21 | Belgium | USD 273 mn | 0.7% | USD 438 mn | 4.9% |
| 22 | Indonesia | USD 273 mn | 0.7% | USD 657 mn | 9.2% |
| 23 | Argentina | USD 204 mn | 0.5% | USD 329 mn | 4.9% |
| 24 | Sweden | USD 204 mn | 0.5% | USD 329 mn | 4.9% |
| 25 | Taiwan | USD 204 mn | 0.5% | USD 329 mn | 4.9% |
| Rest of world | USD 2.0 bn | 4.9% | USD 3.4 bn | 5.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- GSK
- AstraZeneca
- Boehringer Ingelheim
- Chiesi
- Novartis
- Teva
Group 2: Regional and specialist players
- Cipla
- Viatris
- PARI
- Trudell Medical
- Aptar Pharma
- Orion Corporation
- Vectura
- Hovione
- Recipharm
- Omron Healthcare
Group 3: Emerging and niche players
- Aerogen
- Lupin
- Glenmark
- MannKind
- Liquidia
- Bespak
- Merxin
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the inhalation drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 5.5% is calculated from the resulting values.
The market is divided by device type, by indication, by drug class, by age group, by distribution. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the inhalation drug delivery market?
The global inhalation drug delivery market is estimated at USD 38.0 bn in 2025 and USD 40.1 bn in 2026.
How fast will the inhalation drug delivery market grow?
It is forecast to reach USD 68.5 bn by 2036, a compound annual growth rate of 5.5% from 2026, an increase of USD 28.4 bn.
Which country is the largest market for inhalation drug delivery?
United States is the largest market by revenue at USD 18.0 bn in 2026, 45.0% of the global total. The three largest countries together hold 59.0%.
Which country is growing fastest?
Among the ten largest markets, Brazil is growing fastest at 7.0% a year from 2026 to 2036.
Which inhalation drug delivery segment is largest?
In the by device type split, Metered-dose inhalers is the largest segment with 42.0% of 2026 revenue.
Who are the leading inhalation drug delivery companies?
Global leaders include GSK, AstraZeneca, Boehringer Ingelheim, Chiesi.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Medical TourismUSD 40.3 bn · 12.0% CAGR
- Electronic Health RecordsUSD 40.9 bn · 7.0% CAGR
- Precision MedicineUSD 42.2 bn · 11.0% CAGR
- BiosimilarsUSD 37.8 bn · 15.0% CAGR
- ImmunoassayUSD 43.5 bn · 6.5% CAGR
- Point of Care TestingUSD 44.9 bn · 7.0% CAGR
- Clinical NutritionUSD 35.3 bn · 7.0% CAGR
- Nasal SprayUSD 35.0 bn · 5.5% CAGR